Search

Your search keyword '"Indenboim, Victoria"' showing total 3 results
Start Over Author "Indenboim, Victoria"
3 results on '"Indenboim, Victoria"'

1. The Association Between Prebooster Vaccination Antibody Levels and the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Author

Barda, Noam, primary, Canetti, Michal, additional, Gilboa, Mayan, additional, Asraf, Keren, additional, Indenboim, Victoria, additional, Weiss-Ottolenghi, Yael, additional, Amit, Sharon, additional, Zubli, Daniel, additional, Doolman, Ram, additional, Mendelson, Ella, additional, Freedman, Laurence S, additional, Kreiss, Yitshak, additional, Lustig, Yaniv, additional, and Regev-Yochay, Gili, additional

Published
2022
Full Text
View/download PDF

2. Comparing immunogenicity and efficacy of two different mRNA-based COVID-19 vaccines as a fourth dose; six-month follow-up, Israel, 27 December 2021 to 24 July 2022

Author

Barda, Noam, primary, Canetti, Michal, additional, Gilboa, Mayan, additional, Indenboim, Victoria, additional, Asraf, Keren, additional, Weiss-Ottolenghi, Yael, additional, Amit, Sharon, additional, Zibly, Daniel, additional, Doolman, Ram, additional, Mendelson, Ella, additional, Harats, Dror, additional, Freedman, Laurence S., additional, Kreiss, Yitshak, additional, Lustig, Yaniv, additional, and Regev-Yochay, Gili, additional

Published
2022
Full Text
View/download PDF

3. The Association Between Prebooster Vaccination Antibody Levels and the Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection.

Author

Barda, Noam, Canetti, Michal, Gilboa, Mayan, Asraf, Keren, Indenboim, Victoria, Weiss-Ottolenghi, Yael, Amit, Sharon, Zubli, Daniel, Doolman, Ram, Mendelson, Ella, Freedman, Laurence S, Kreiss, Yitshak, Lustig, Yaniv, and Regev-Yochay, Gili

Subjects
COVID-19, IMMUNOGLOBULINS, COVID-19 vaccines, RISK assessment, RESEARCH funding, VIRAL antibodies, LONGITUDINAL method
Abstract

The correlation between anti–severe acute respiratory syndrome coronavirus 2 antibody levels and infection was reported. Here, we estimated the role of pre–fourth dose levels using data from 1098 healthcare workers. The risk of infection was reduced by 46% (95% confidence interval, 29%–59%) for each 10-fold increase in prebooster levels. Prebooster antibody levels could be used to optimally time boosters. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results